PMID- 19758204
OWN - NLM
STAT- MEDLINE
DCOM- 20091029
LR  - 20111117
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1173
DP  - 2009 Sep
TI  - Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte 
      antigen class II alleles in chronic fatigue syndrome: are they associated with 
      age at onset and specific symptoms?
PG  - 589-99
LID - 10.1111/j.1749-6632.2009.04802.x [doi]
AB  - This study aimed to determine the influence of autoantibodies, polymorphisms in 
      the serotonin pathway, and human leukocyte antigen (HLA) class II genes on age at 
      chronic fatigue syndrome (CFS) onset and symptoms. Eighty-one CFS patients were 
      enrolled, and clinical data were recorded. Autoantibodies to different components 
      of the central nervous system were tested. Polymorphisms in the promoter of the 
      serotonin transporter gene (l/s) and a single nucleotide polymorphism in the 
      serotonin receptor-2A gene (A/G) as well as HLA class II alleles were determined. 
      Multivariate logistic-regression analyses were carried out. The mean age at CFS 
      onset +/- SD was 33.5 +/- 12.5 years. An age at CFS onset (ACFSO) during the 
      third decade of life was associated with the serotonin receptor AA genotype and 
      the HLA-DRB1*03 allele. An ACFSO during the fourth decade of life was associated 
      with the HLA-DRB1*07 allele, whereas an ACFSO > or = 43 years was associated with 
      having at least one copy of the serotonin G allele. Concerning CFS symptoms, the 
      serotonin AG genotype was protective against depressive symptoms. Although having 
      at least one copy of the serotonin A allele and being female were associated with 
      risk for arthralgia, the presence of antineuronal cell antibodies was protective 
      against this. Episodes of unexplained fever were associated with the HLA-DRB1*11 
      allele. None of the genetic or serological features was associated with myalgia. 
      None of the antibodies determined correlated with any ACFSO or other symptoms. 
      Our results reveal that in CFS, like other autoimmune diseases, different genetic 
      features are related to age at CFS onset and symptoms.
FAU - Ortega-Hernandez, Oscar-Danilo
AU  - Ortega-Hernandez OD
AD  - Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical 
      Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Cuccia, Mariaclara
AU  - Cuccia M
FAU - Bozzini, Sara
AU  - Bozzini S
FAU - Bassi, Nicola
AU  - Bassi N
FAU - Moscavitch, Samuel
AU  - Moscavitch S
FAU - Diaz-Gallo, Lina-Marcela
AU  - Diaz-Gallo LM
FAU - Blank, Miri
AU  - Blank M
FAU - Agmon-Levin, Nancy
AU  - Agmon-Levin N
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 0 (Autoantibodies)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Receptor, Serotonin, 5-HT2A)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Age of Onset
MH  - Alleles
MH  - Arthralgia/genetics/immunology
MH  - Autoantibodies/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fatigue Syndrome, Chronic/epidemiology/*genetics/immunology
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Italy
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Polymorphism, Genetic
MH  - Receptor, Serotonin, 5-HT2A/*genetics
MH  - Risk Factors
MH  - Serotonin Plasma Membrane Transport Proteins/*genetics
MH  - Sex Factors
MH  - Young Adult
EDAT- 2009/09/18 06:00
MHDA- 2009/10/30 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2009/10/30 06:00 [medline]
AID - NYAS4802 [pii]
AID - 10.1111/j.1749-6632.2009.04802.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2009 Sep;1173:589-99. doi: 10.1111/j.1749-6632.2009.04802.x.